KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Current Deferred Revenue (2016 - 2023)

Historic Current Deferred Revenue for Palvella Therapeutics (PVLA) over the last 9 years, with Q3 2023 value amounting to $994000.0.

  • Palvella Therapeutics' Current Deferred Revenue fell 9462.64% to $994000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $994000.0, marking a year-over-year decrease of 9462.64%. This contributed to the annual value of $20.8 million for FY2022, which is 1708.87% down from last year.
  • As of Q3 2023, Palvella Therapeutics' Current Deferred Revenue stood at $994000.0, which was down 9462.64% from $17.7 million recorded in Q2 2023.
  • In the past 5 years, Palvella Therapeutics' Current Deferred Revenue ranged from a high of $28.4 million in Q2 2019 and a low of $994000.0 during Q3 2023
  • Moreover, its 5-year median value for Current Deferred Revenue was $20.8 million (2022), whereas its average is $18.9 million.
  • In the last 5 years, Palvella Therapeutics' Current Deferred Revenue soared by 22275.03% in 2021 and then tumbled by 9462.64% in 2023.
  • Quarter analysis of 5 years shows Palvella Therapeutics' Current Deferred Revenue stood at $11.3 million in 2019, then increased by 12.18% to $12.6 million in 2020, then skyrocketed by 98.91% to $25.1 million in 2021, then fell by 17.09% to $20.8 million in 2022, then tumbled by 95.23% to $994000.0 in 2023.
  • Its Current Deferred Revenue stands at $994000.0 for Q3 2023, versus $17.7 million for Q2 2023 and $26.7 million for Q1 2023.